Stephens Consulting’s Xeris Biopharma Holdings XERS Stock Holding History

Stephens Consulting’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-65	Closed	-$357	–	2030
2025 Q1	$357	Buy	+65	New	+$262	﹤0.01%	1296

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stephens Consulting's XERS Position: Q2 2025 in Review

Stephens Consulting sold out of Xeris Biopharma Holdings (XERS) in Q2 2025, closing a stake of 65 shares — an estimated $357 sold.

Stephens Consulting first reported a position in XERS in Q1 2025 and held it in 1 quarter. The position peaked at $357 in Q1 2025. 200 funds tracked by Wall St. Rank hold XERS as of Q2 2025.

Stephens Consulting reported no remaining Xeris Biopharma Holdings position as of Q2 2025 after selling out during the quarter.
Stephens Consulting sold 65 Xeris Biopharma Holdings shares in Q2 2025, an estimated $357.
Stephens Consulting first reported a position in Xeris Biopharma Holdings in Q1 2025 and held it in 1 quarter.
Stephens Consulting's Xeris Biopharma Holdings position peaked at $357 in Q1 2025.
200 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2025.

Based on Stephens Consulting's 13F filing for Q2 2025, filed 25 Jul 2025.